-
公开(公告)号:US20070031437A1
公开(公告)日:2007-02-08
申请号:US11546760
申请日:2006-10-12
申请人: Ellen Filvaroff , Weilan Ye , Leon Parker , Jo-Anne Hongo , Maike Schmidt
发明人: Ellen Filvaroff , Weilan Ye , Leon Parker , Jo-Anne Hongo , Maike Schmidt
IPC分类号: A61K39/395
CPC分类号: A61K31/7088 , A61K2039/505 , C07K16/22
摘要: The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
摘要翻译: 本发明提供使用EGFL7拮抗剂调节血管发育的方法。 本文还提供筛选EGFL7活性调节剂的方法。 此外,提供了使用EGFL7拮抗剂的治疗方法。
-
公开(公告)号:US20100203041A1
公开(公告)日:2010-08-12
申请号:US12280673
申请日:2007-03-16
申请人: Weilan Ye , Maike Schmidt , Jo-Anne Hongo , Yan Wu
发明人: Weilan Ye , Maike Schmidt , Jo-Anne Hongo , Yan Wu
IPC分类号: A61K39/395 , C07K16/22 , C07H21/04 , A61P35/04 , A61P35/00 , A61P27/06 , A61P37/06 , A61P17/06 , A61P9/10 , C12N15/74 , C12N1/21 , C12N5/10 , C12P21/00
CPC分类号: C07K16/22 , A61K2039/505 , A61K2039/507 , C07K2317/56 , C07K2317/565 , C07K2317/73
摘要: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
摘要翻译: 本发明提供抗EGFL7抗体,以及组合物和使用这些抗体的方法。
-
公开(公告)号:US08398976B2
公开(公告)日:2013-03-19
申请号:US13087247
申请日:2011-04-14
申请人: Weilan Ye , Maike Schmidt , Jo-Anne Hongo , Yan Wu
发明人: Weilan Ye , Maike Schmidt , Jo-Anne Hongo , Yan Wu
IPC分类号: A61K39/395
CPC分类号: C07K16/22 , A61K2039/505 , A61K2039/507 , C07K2317/56 , C07K2317/565 , C07K2317/73
摘要: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
摘要翻译: 本发明提供抗EGFL7抗体,以及组合物和使用这些抗体的方法。
-
公开(公告)号:US20110200602A1
公开(公告)日:2011-08-18
申请号:US13087247
申请日:2011-04-14
申请人: Weilan Ye , Maike Schmidt , Jo-Anne Hongo , Yan Wu
发明人: Weilan Ye , Maike Schmidt , Jo-Anne Hongo , Yan Wu
IPC分类号: C07K16/22 , A61K39/395 , C12N15/13 , C12N15/85 , C12N5/07 , C12N1/00 , A61P35/04 , A61P27/00
CPC分类号: C07K16/22 , A61K2039/505 , A61K2039/507 , C07K2317/56 , C07K2317/565 , C07K2317/73
摘要: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
摘要翻译: 本发明提供抗EGFL7抗体,以及组合物和使用这些抗体的方法。
-
公开(公告)号:US20090297512A1
公开(公告)日:2009-12-03
申请号:US12357819
申请日:2009-01-22
IPC分类号: A61K39/395 , A61P35/00
CPC分类号: A61K31/7088 , A61K2039/505 , C07K16/22
摘要: The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
摘要翻译: 本发明提供使用EGFL7拮抗剂调节血管发育的方法。 本文还提供筛选EGFL7活性调节剂的方法。 此外,提供了使用EGFL7拮抗剂的治疗方法。
-
公开(公告)号:US20120003208A1
公开(公告)日:2012-01-05
申请号:US12904813
申请日:2010-10-14
IPC分类号: A61K39/395 , A61P35/00
CPC分类号: A61K31/7088 , A61K2039/505 , C07K16/22
摘要: The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
摘要翻译: 本发明提供使用EGFL7拮抗剂调节血管发育的方法。 本文还提供筛选EGFL7活性调节剂的方法。 此外,提供了使用EGFL7拮抗剂的治疗方法。
-
公开(公告)号:US08790646B2
公开(公告)日:2014-07-29
申请号:US12904813
申请日:2010-10-14
IPC分类号: A61K39/395
CPC分类号: A61K31/7088 , A61K2039/505 , C07K16/22
摘要: The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
摘要翻译: 本发明提供使用EGFL7拮抗剂调节血管发育的方法。 本文还提供筛选EGFL7活性调节剂的方法。 此外,提供了使用EGFL7拮抗剂的治疗方法。
-
公开(公告)号:US20080305106A1
公开(公告)日:2008-12-11
申请号:US11568901
申请日:2005-04-12
申请人: Jane Brennan , Frederic J. de Sauvage , Ellen Filvaroff , Iqbal Grewal , Bryan Irving , Jagath Reddy Junutula , Daniel Kirchhofer , Franklin Peale , Heide Phillips , Tracy Tang , Dineli Wickramasinghe , Weilan Ye
发明人: Jane Brennan , Frederic J. de Sauvage , Ellen Filvaroff , Iqbal Grewal , Bryan Irving , Jagath Reddy Junutula , Daniel Kirchhofer , Franklin Peale , Heide Phillips , Tracy Tang , Dineli Wickramasinghe , Weilan Ye
IPC分类号: A61K39/395 , C12Q1/68 , C12N5/06 , A61K38/00 , A61P19/00 , A61P27/00 , A01K67/027 , C07K16/18
CPC分类号: A01K67/0275 , A01K67/0278 , A01K2217/05 , A01K2217/072 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C07K14/4703 , C07K14/705 , C12N15/8509
摘要: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO256, PRO34421, PRO334, PRO770, PRO983, PRO1009, PRO1107, PRO1158, PRO1250, PRO1317, PRO4334, PRO4395, PRO49192, PRO9799, PRO21175, PRO19837, PRO21331, PRO23949, PRO697 or PRO1480 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
摘要翻译: 本发明涉及转基因动物,以及与基因功能表征相关的组合物和方法。 具体地,本发明提供转基因小鼠,其包括PRO256,PRO34421,PRO334,PRO770,PRO983,PRO1009,PRO1107,PRO1158,PRO1250,PRO1317,PRO4334,PRO4395,PRO49192,PRO9799,PRO21175,PRO19837,PRO21331,PRO23949,PRO697或PRO1480中的中断 基因。 这样的体内研究和表征可以提供有用的识别和发现治疗和/或治疗用于预防,改善或矫正与基因中断相关的疾病或功能障碍如神经障碍; 心血管,内皮或血管生成障碍; 眼睛异常; 免疫学障碍; 肿瘤疾病; 骨代谢异常或障碍; 脂代谢紊乱 或发育异常。
-
公开(公告)号:US20120148572A1
公开(公告)日:2012-06-14
申请号:US13112833
申请日:2011-05-20
申请人: Wei-Ching Liang , Gregory D. Plowman , Yan Wu , Weilan Ye
发明人: Wei-Ching Liang , Gregory D. Plowman , Yan Wu , Weilan Ye
IPC分类号: A61K39/395 , C12N9/96 , C12N15/13 , C12N15/63 , C12N5/16 , A61P9/00 , A61P35/00 , A61P27/02 , G01N33/566 , C07K16/28 , C12P21/02
CPC分类号: C07K16/2842 , A61K2039/505 , A61K2039/507 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要: The present invention relates to the use of VEGF antagonists and a novel anti-α5β1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-α5β1 antibodies and methods of making and using them.
摘要翻译: 本发明涉及VEGF拮抗剂和新型抗α5抗体用于治疗癌症并抑制血管生成和/或血管通透性的用途,包括抑制疾病中的异常血管生成。 本发明还涉及包含新的抗α5和bgr1抗体的组合物和试剂盒,以及制备和使用它们的方法。
-
公开(公告)号:US20100129375A1
公开(公告)日:2010-05-27
申请号:US12557394
申请日:2009-09-10
申请人: Harald J. Junge , Weilan Ye
发明人: Harald J. Junge , Weilan Ye
IPC分类号: A61K39/395 , A61K38/00 , A61P27/02
CPC分类号: C07K16/28 , A61K38/177 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/705 , C07K16/18 , C07K16/22 , C07K2317/34 , C07K2317/76
摘要: The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders.
摘要翻译: 本发明提供了使用TSPAN12和Norrin拮抗剂抑制眼血管发育和治疗相关疾病的方法。
-
-
-
-
-
-
-
-
-